pnu-282987 and Cognition-Disorders

pnu-282987 has been researched along with Cognition-Disorders* in 1 studies

Other Studies

1 other study(ies) available for pnu-282987 and Cognition-Disorders

Article	Year
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationsh Journal of medicinal chemistry, 2006, Jul-13, Volume: 49, Issue:14 N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha7 neuronal nicotinic acetylcholine receptor (alpha7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition. Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Biological Availability; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cognition Disorders; Drug Stability; Ether-A-Go-Go Potassium Channels; Evoked Potentials, Auditory; Humans; In Vitro Techniques; Learning; Male; Memory; Microsomes, Liver; Neurons; Nicotinic Agonists; Nootropic Agents; Patch-Clamp Techniques; Quinuclidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Recognition, Psychology; Schizophrenia; Stereoisomerism; Structure-Activity Relationship	2006

Article

Year

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationsh

Journal of medicinal chemistry, 2006, Jul-13, Volume: 49, Issue:14

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha7 neuronal nicotinic acetylcholine receptor (alpha7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.

Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Biological Availability; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cognition Disorders; Drug Stability; Ether-A-Go-Go Potassium Channels; Evoked Potentials, Auditory; Humans; In Vitro Techniques; Learning; Male; Memory; Microsomes, Liver; Neurons; Nicotinic Agonists; Nootropic Agents; Patch-Clamp Techniques; Quinuclidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Recognition, Psychology; Schizophrenia; Stereoisomerism; Structure-Activity Relationship

2006